The safety record is generally placebo-like, but several specific findings deserve attention
BPC-157 and TB-500 Dosage Protocol BPC-157: 250500mcg daily, injected subcutaneously near the injury site TB-500: 22.5mg twice weekly (loading phase) for 46 weeks, then 2mg once weekly (maintenance phase) The combination is typically used for 612 weeks, depending on injury severity and healing progress
368 Such delivery systems largely improved the drug accumulation in brain tumor via homologous binding mechanism
An article suggests that epitalon, along with epithalamine, might be useful in the prevention of breast cancer in women who are at risk [8]
Why You'll See Different Answers Across Studies Published research on GHK-Cu doesn't converge on one number because study designs vary widely
They have no incentive to fast-track things that work. The competing forces working to expand and limit the reach of BPC-157 highlight the strange tension that defines the wellness and biohacking spaces in 2026